{"product_id":"supn-bcg-matrix","title":"(SUPN) Supernus Pharmaceuticals, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Supernus Pharmaceuticals, Inc. BCG Matrix is a company-specific strategic tool used to assess the portfolio across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQelbree, ADHD ages 6 to 17\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQelbree is Supernus Pharmaceuticals, Inc.’s main growth brand and is approved for ADHD in children and adolescents ages 6 to 17. It sits in a large CNS market, where Supernus has kept growing prescriptions, so it fits the Star role in the BCG matrix going into end-2025. For BCG, this is the clearest high-growth, high-share asset in the portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGOCOVRI, Parkinson’s dyskinesia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGOCOVRI is Supernus Pharmaceuticals, Inc.'s niche neurology Star: it treats levodopa-induced dyskinesia, a movement side effect that can affect long-term Parkinson’s patients. Parkinson’s disease affects nearly 1 million people in the U.S., and about 90,000 new cases are diagnosed each year, leaving room for deeper use. Its recurring use profile and focused patient base support steady growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMYOBLOC, botulinum toxin Type B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMYOBLOC, a botulinum toxin Type B, is approved for adult cervical dystonia and sialorrhea, so it sits in a durable specialty niche with repeat injection cycles. Its established use and specialist prescribing support steady demand, even in a mature market. Supernus Pharmaceuticals, Inc. can treat it as a Star if recent sales growth and share gains stay ahead of the broader neurology injectables market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-stimulant ADHD franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals, Inc. has a real non-stimulant ADHD niche through Qelbree, and that matters because demand for ADHD options that avoid stimulant risks stays strong. In a market where non-stimulants still take a small share versus stimulants, a differentiated CNS franchise can keep building share and pricing power.\u003c\/p\u003e\n\u003cp\u003eThat makes this a Star-like asset: it sits in a growing category and Supernus Pharmaceuticals, Inc. has one of the few meaningful presences there. If uptake keeps rising, the franchise can scale into a larger share of Supernus Pharmaceuticals, Inc. revenue over time.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQelbree anchors the non-stimulant ADHD franchise.\u003c\/li\u003e\n\u003cli\u003eDemand for alternatives remains structurally high.\u003c\/li\u003e\n\u003cli\u003eGrowth runway supports Star classification.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUS neurology specialty sales platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals, Inc. uses a focused U.S. neurology sales platform that sells through wholesalers, specialty pharmacies, and authorized distributors. That setup fits complex CNS brands, where access and targeted promotion matter more than broad retail reach.\u003c\/p\u003e\n\u003cp\u003eIn BCG terms, this is a support asset that can help \"Stars\" scale faster by lowering launch friction and improving payer and prescriber reach. The model is built to keep neurology brands close to specialists, not spread sales effort thin.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocused neurology reach\u003c\/li\u003e\n\u003cli\u003eThree-channel U.S. access model\u003c\/li\u003e\n\u003cli\u003eSupports faster brand uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQelbree Leads Supernus’s CNS Growth Story\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQelbree is Supernus Pharmaceuticals, Inc.’s clearest Star because it leads the company’s growth in a large non-stimulant ADHD market. GOCOVRI adds a second Star-like neurology niche, while MYOBLOC supports steady repeat demand in specialty care. Together, they give Supernus Pharmaceuticals, Inc. a focused CNS growth base.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar asset\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQelbree\u003c\/td\u003e\n\u003ctd\u003eGrowth driver\u003c\/td\u003e\n\u003ctd\u003eNon-stimulant ADHD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGOCOVRI\u003c\/td\u003e\n\u003ctd\u003eNiche Star\u003c\/td\u003e\n\u003ctd\u003eParkinsons side effects\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMYOBLOC\u003c\/td\u003e\n\u003ctd\u003eSteady niche\u003c\/td\u003e\n\u003ctd\u003eRepeat specialist use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBCG Matrix of Supernus Pharmaceuticals shows which drugs are Stars, Cash Cows, Question Marks, or Dogs, guiding invest\/hold\/divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eClean BCG Matrix view of Supernus Pharmaceuticals, Inc. to quickly spot growth, cash, and drag.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for Supernus Pharmaceuticals, Inc. that strengthens credibility and speeds investor due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrokendi XR, extended-release topiramate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrokendi XR is a mature extended-release topiramate brand for epilepsy and migraine prevention. In BCG terms, it fits a Cash Cow: low growth, high cash conversion, and long-run residual demand even as generic pressure keeps sales shrinking. Its value is mainly in harvesting cash, not driving future growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOxtellar XR, oxcarbazepine ER\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOxtellar XR (oxcarbazepine ER) is approved for partial-onset seizures in patients 6 years and older, so it serves a defined epilepsy niche rather than a fast-growth market. In 2025, Supernus Pharmaceuticals reported total revenue of about $600 million, and mature brands like this help fund cash flow with low growth needs. That makes Oxtellar XR a classic Cash Cow: steady demand, limited upside, and dependable support for the portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPOKYN, advanced Parkinson’s rescue therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAPOKYN is Supernus Pharmaceuticals, Inc.'s rescue therapy for acute off episodes in advanced Parkinson’s disease, so it fits a narrow but recurring need. That makes it a classic Cash Cow: steady repeat use, low incremental marketing spend, and limited competition in a mature niche. Its value comes from reliable maintenance of an established patient base, not fast growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eXADAGO, PD adjunct therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXADAGO, a safinamide add-on to levodopa\/carbidopa for Parkinson’s off periods, sits in a small, mature niche with limited upside. That fits a Cash Cow: steady, established use, low growth, and likely modest but durable cash flow rather than a big expansion engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdjunct only, not core growth\u003c\/li\u003e\n\u003cli\u003eTargets PD off-periods\u003c\/li\u003e\n\u003cli\u003eMature niche product\u003c\/li\u003e\n\u003cli\u003eCash flow over expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOsmolex ER, PD and EPS treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOsmolex ER is an older branded CNS cash cow for Supernus Pharmaceuticals, Inc.: it is approved for Parkinson’s disease and drug-induced extrapyramidal reactions in adults, so the addressable market is narrow and expansion upside is limited. That said, mature branded demand can still throw off steady cash with low ongoing support costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eApproved for PD and drug-induced EPS\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eOlder brand, limited growth runway\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eStable sales can fund cash flow\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLow support spend helps margins\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupernus’ Cash Cows Keep the Revenue Engine Running\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals, Inc.'s Cash Cows are mature CNS brands that still convert steady demand into cash. In 2025, Supernus Pharmaceuticals, Inc. reported about $600 million in revenue, and these products help fund the portfolio with low growth needs. Their value is cash generation, not expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrokendi XR\u003c\/td\u003e\n\u003ctd\u003eHarvest cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPOKYN\u003c\/td\u003e\n\u003ctd\u003eStable niche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOsmolex ER\u003c\/td\u003e\n\u003ctd\u003eLow-growth cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eSupernus Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact Supernus Pharmaceuticals, Inc. BCG Matrix document you’ll receive after purchase. The full file is the same professionally formatted version—no mockups, no watermark, no demo content. Once purchased, it’s ready for immediate download, editing, printing, or sharing. What you see here is exactly what you’ll own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric-pressured Trokendi XR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeneric-pressured Trokendi XR fits the Dogs bucket because topiramate ER now faces multiple generics, which has cut pricing power and eroded share. In Supernus Pharmaceuticals, Inc., this franchise offers limited growth and weak long-term economics versus higher-value products. With the market commoditized, revenue tends to stay under pressure instead of expanding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall-share Oxtellar XR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOxtellar XR sits in a mature seizure market led by larger epilepsy brands, so its growth runway is narrow. Its low-single-digit share and niche use limit expansion, which fits Dog status in the BCG Matrix. Supernus Pharmaceuticals, Inc. is better off treating it as a cash-preservation brand than a growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-volume APOKYN\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAPOKYN fits the question mark-to-dog logic in Supernus Pharmaceuticals, Inc.’s BCG Matrix: it serves a narrow Parkinson’s rescue-use niche, so the addressable market is small. The U.S. has about 1 million people living with Parkinson’s disease, but APOKYN’s on-demand use keeps volume limited. That means low share, low growth, and weak scale economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow-volume XADAGO\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXADAGO is a small adjunctive Parkinson’s franchise, so it sits in Dog territory in BCG terms. Supernus has limited room to scale it because the drug serves a narrow add-on niche, not a broad chronic-use base. In 2025\/2026 filings, Supernus did not show a large standalone growth engine here, which supports a low-share, low-growth view.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall Parkinson’s add-on market\u003c\/li\u003e\n\u003cli\u003eLimited expansion runway\u003c\/li\u003e\n\u003cli\u003eLow BCG strategic priority\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNiche Osmolex ER use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOsmolex ER is a narrow-use brand for Parkinson’s disease and drug-induced extrapyramidal reactions, so its market stays small and the growth path is limited. In Supernus Pharmaceuticals, Inc.’s portfolio, that makes it a classic Dog: low-growth, niche demand, and only modest commercial traction. The asset is more of a tail product than a growth engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTwo labeled uses only\u003c\/li\u003e\n\u003cli\u003eSmall addressable patient base\u003c\/li\u003e\n\u003cli\u003eModest uptake limits scale\u003c\/li\u003e\n\u003cli\u003eLow-growth tail asset\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupernus’ Dogs: Niche Brands, Weak Growth, Cash Harvest\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs in Supernus Pharmaceuticals, Inc. are the low-share, low-growth brands: Trokendi XR faces generic erosion, Oxtellar XR is mature, and APOKYN, XADAGO, and Osmolex ER serve small niche markets. APOKYN is tied to a U.S. Parkinson’s pool of about 1 million people, but on-demand use keeps scale weak. These assets look better for cash harvest than growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003cth\u003eKey fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrokendi XR\u003c\/td\u003e\n\u003ctd\u003eGeneric pressure\u003c\/td\u003e\n\u003ctd\u003eMultiple generics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPOKYN\u003c\/td\u003e\n\u003ctd\u003eNiche use\u003c\/td\u003e\n\u003ctd\u003e~1M Parkinson’s patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSPN-830, late-stage PD device combo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSPN-830 is a late-stage drug-device combo for Parkinson’s off episodes, aimed at a large need: about 1 million people in the U.S. live with Parkinson’s, and roughly 40% to 50% develop motor fluctuations. It still faces FDA approval risk and then the harder test of uptake. That mix of high need, high uncertainty, and possible upside fits a Question Mark.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSPN-817, Phase I severe epilepsy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSPN-817 is still in Phase I for severe epilepsy, so it has no commercial share yet and carries very high clinical risk. At this stage, Supernus Pharmaceuticals, Inc. must fund early testing before any proof of efficacy, safety, or market value. Phase I assets like this are classic Question Marks in the BCG Matrix because success is uncertain and cash needs are high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSPN-820, Phase II resistant depression\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSPN-820 is in Phase II for treatment-resistant depression, a market affecting about 30% of major depressive disorder patients. The opportunity is large, but Supernus Pharmaceuticals, Inc. has not yet shown clinical proof, so the asset stays a Question Mark in BCG terms. If Phase II data improve, it could shift toward Star status; if not, it likely stays low-value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSPN-443, preclinical CNS program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSPN-443 is a preclinical CNS asset, so it has no human efficacy data, no approved label, and effectively 0% market share today. In BCG terms, that puts it in Question Marks: high scientific upside, but also a high chance of failure before any sales can start. For Supernus Pharmaceuticals, Inc., value here depends on whether early data can justify moving into clinical testing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePreclinical only\u003c\/li\u003e\n\u003cli\u003eNo human proof yet\u003c\/li\u003e\n\u003cli\u003eZero current market share\u003c\/li\u003e\n\u003cli\u003eHigh-upside, high-risk asset\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSPN-446, preclinical CNS program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSPN-446 is a preclinical CNS program, so it fits the Question Mark bucket: high scientific upside, but no clear path to revenue yet. As of Supernus Pharmaceuticals, Inc.'s latest reported 2025 results, the Company generated $661.8 million in total revenue, but SPN-446 has not advanced far enough to move the needle today. Preclinical assets like this need proof-of-concept data before they can justify more capital.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly stage, no commercialization yet\u003c\/li\u003e\n\u003cli\u003ePotential upside, but high failure risk\u003c\/li\u003e\n\u003cli\u003eNeeds clinical data to re-rate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupernus’ Early CNS Bets: High Upside, No Sales Yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals, Inc. Question Marks are its early CNS bets: SPN-830, SPN-817, SPN-820, SPN-443, and SPN-446. They have high upside but no current market share, and all depend on clinical or FDA proof before they can add sales; Supernus Pharmaceuticals, Inc. reported $661.8 million in 2025 revenue, so these assets are still value drivers only in the future.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSPN-830\u003c\/td\u003e\n\u003ctd\u003eLate stage\u003c\/td\u003e\n\u003ctd\u003eApproval risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSPN-817\u003c\/td\u003e\n\u003ctd\u003ePhase I\u003c\/td\u003e\n\u003ctd\u003eVery high risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSPN-820\u003c\/td\u003e\n\u003ctd\u003ePhase II\u003c\/td\u003e\n\u003ctd\u003eUnproven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSPN-443\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003eNo human data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSPN-446\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003eNo revenue yet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235082215689,"sku":"supn-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/supn-bcg-matrix.webp?v=1785732889","url":"https:\/\/dcfanalyst.com\/products\/supn-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}